$EBS

5 stories mentioning EBSUpdated 19h ago

Every FINWIRES story that references EBS, newest first.

Sector Update: Healthcare Stocks Mixed Late Afternoon

Healthcare stocks were mixed late Thursday afternoon, with the NYSE Healthcare Index fractionally higher and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.1%.The iShares Biotechnology ETF (IBB) was up 0.4%.In corporate news, Emergent BioSolutions (EBS) shares dropped 30% after it cut its full-year guidance and announced an organizational restructuring plan.Becton, Dickinson (BDX) raised its full-year earnings guidance as the medical device maker's Q3 results exceeded Wall Street's estimates amid revenue gains across all divisions. Its shares gained 3.5%.Enovis (ENOV) shares fell 13% after the company reported its results for fiscal Q2.Braveheart Bio (BRVE) shares surged 70% in its Nasdaq debut Thursday, after the company announced an upsized IPO of 21.25 million common shares late Wednesday.

$BDX$BRVE$EBS$ENOV

Sectors1d ago

Sector Update: Healthcare

Healthcare stocks edged higher late Thursday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding 0.1%.The iShares Biotechnology ETF (IBB) was up 0.3%.In corporate news, Emergent BioSolutions (EBS) shares fell past 31% after it cut its full-year guidance and announced an organizational restructuring plan.

$EBS

Wire1d ago

Emergent BioSolutions Shares Plunge After 2026 Guidance Cut, Restructuring

Emergent BioSolutions (EBS) shares fell 31% in Thursday trading after the company cut its full-year guidance and announced an organizational restructuring plan.The company reported Q2 adjusted earnings late Wednesday of $0.60 per diluted share, up from $0.24 a year earlier.Two analysts surveyed by FactSet expected a loss of $0.09.Revenue for the quarter ended June 30 was $234.3 million, up from $140.9 million a year earlier.Two analysts expected $177.5 million.For 2026, the company lowered its revenue guidance to $645 million to $675 million from the prior forecast of $720 million to $760 million. Two analysts expect $693.1 million.Also, the company disclosed a restructuring plan, that will lead to reduction of approximately 90 roles, eliminate 21 positions that are currently vacant, and closure of its wet laboratories in Gaithersburg, Maryland. The company also plans to eliminate the role of chief medical officer, head of research and development.Price: $5.17, Change: $-2.38, Percent Change: -31.50%

$EBS

Wire100d ago

Emergent BioSolutions Signs $50 Million Contract to Support SAB Biotherapeutics' Lead Program

Emergent BioSolutions (EBS) said Wednesday it has signed a $50 million multi-year agreement with SAB Biotherapeutics (SABS) to help advance SAB-142 lead program in clinical development for autoimmune type 1 diabetes.Under the agreement, $36 million is contingent on future regulatory approval and downstream milestones, according to a statement.Emergent BioSolutions will provide end-to-end development and manufacturing services that are compliant with current good manufacturing practices, the company said.Price: $8.17, Change: $-0.07, Percent Change: -0.79%

$EBS$SABS

Wire101d ago

Emergent BioSolutions Signs $34.5 Million Manufacturing Deal With Substipharm Biologics

Emergent BioSolutions (EBS) said Tuesday it has signed a $34.5 million deal with Substipharm Biologics to support drug substance manufacturing for the Japanese encephalitis vaccine at its Canton, Massachusetts, facility.As part of the agreement, Emergent said it will be the exclusive distributor of the vaccine to the US government, following potential US Food and Drug Administration regulatory clearances.Under a master manufacturing services agreement, Emergent said it will conduct operational and regulatory inspection readiness activities for the vaccine.Emergent shares were up 1.6% in Tuesday trading.Price: $8.16, Change: $+0.13, Percent Change: +1.62%

$EBS

Track with the FINWIRES app suite

FolioX

Track EBS in your portfolio

WheelAI

Analyze EBS options with the wheel strategy

StockInsider

See market sentiment on EBS